Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... day, their baby stopped breathing, his collapsed bronchus blocking ... and Bryan Gionfriddo watched helplessly, just praying that somehow ... doctors said he had a good chance of not ... now 20-month-old son, Kaiba. "At that point, we were ... and run with it." , They found hope at ...
(Date:5/23/2013)... May 23, 2013 Venaxis, Inc. (Nasdaq:   ... on obtaining FDA clearance and commercializing its rapid, protein ... pricing of an underwritten public offering of 10,000,000 shares ... 3,500,000 shares of its common stock at an exercise ... offering price of $1.25 per share and related warrant.  ...
(Date:5/23/2013)... May 23, 2013  BioScrip, Inc. (NASDAQ: ... at the Jefferies 2013 Global Healthcare Conference to be ... York. Richard Smith , ... Tran , Chief Financial Officer, will present on ... Time.   About BioScrip BioScrip, Inc. ...
(Date:5/23/2013)... Can economic incentives such as gift ... of the public to increase their donations of blood? ... Carey Business School Assistant Professor Mario Macis says ... large body of recent research that supports their argument, ... issue of Science that the World Health Organization and ...
Breaking Biology Technology:Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... out that "free" services can be profitable after all. ... this month it would hit the elusive goal of ... of hooking up business contacts for free, LinkedIn last ... to $2,000 per year. Acceptance of these premium offerings ...
... big enough that no one is likely to see everything it ... during the marathon event that promises to draw around 20,000 people ... their responses: , , Sal Braico, COO of ConjuGon ... which is part of BIO. They have companies presenting and opportunities ...
... Ten $1,000 scholarships and a top prize of ... entrepreneurs in a business-plan competition sponsored by BizFilings , ... Foundation . , ,The contest, named Plan for the Future, ... May 31. They'll be judged by an independent panel. , ...
Cached Biology Technology:Free can be profitable 2Where will you be at BIO? 2
(Date:5/23/2013)... Science , Automated conserved noncoding ... promoter evolution among grasses , Within the genome ... DNA that undergo little change in position and sequence ... any proteins. Some of these evolutionarily stable sequences, so-called ... expression of other genes or the condensation of chromosomes, ...
(Date:5/23/2013)... said to be the world,s most popular fruit, can ... research with purple GM varieties. , "Working with ... by the addition of a specific compound, allows us ... said Professor Cathie Martin from the John Innes Centre. ... with better flavour, health and shelf life characteristics because ...
(Date:5/23/2013)... Wash. Pacific Northwest National Laboratory honored more ... commercialization of intellectual property at PNNL,s annual Intellectual ... , The Department of Energy national laboratory named ... for his work developing battery materials that can ... the electrical grid, and reduce the time it ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... Singapore,s Institute of Bioengineering and Nanotechnology (IBN) has ... unique surfactant template. This completely new porous structure ... In the current Nature Chemistry ... this novel material, named IBN-9 after the research ...
... 3 The General Services Administration (GSA) has ... provider of Personal Identity Verification (PIV) Enrollment and ... Security Presidential Directive 12 (HSPD-12). With this certification, ... 70 contract under the GSA SIN 132-62 as ...
... April 3, 2009 -- By identifying a novel compound that ... Laboratory and the University of Chicago may be on a ... in Science , a team that includes Tim Tschaplinski ... has a role in priming the immunity response in Arabidopsis, ...
Cached Biology News:First tri-continuous mesoporous Silica complex structure developed in Singapore 2ABBTECH Staffing Services Certified by GSA as an HSPD-12 Managed Service Provider 2Researchers discover primer to plant defense system 2
... slide chambers are vapor-tight adhesive chambers for sealing ... are affixed over a sample on a glass ... two ports, and the ports are then sealed ... and replaced to allow exchange of reaction fluid. ...
... Use : GeneTraffic is built to be ... research. GeneTraffic provides visual and computational tools ... prior to analysis. , Data and ... using the MIAME (Minimum Information About a ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
Biology Products: